Abstract #3600

Intensity-Based Segmentation of Tumor on Multiparametric MRI to Aid Response Assessment of High-Grade Gliomas Treated with Immunoradiotherapy

Harshan Ravi¹, Samuel H. Hawkins^1,2, Olya Stringfield³, Malesa Pereira^1,4,5, Heiko Enderling^6,7, H-H Michael Yu^7,8, John A. Arrington^5,7, Solmaz Sahebjam^7,9,10, and Natarajan Raghunand^1,7

¹Moffitt Cancer Center and Research Center, Tampa, FL, United States, ²Department of Computer Science, Bradley University, Peoria, IL, United States, ³Quantitative Imaging Core, Moffitt Cancer Center and Research Institute, Tampa,, FL, United States, ⁴Behavioral and Community Health Sciences,, LSU Health School of Public Health, New Orleans, LA, United States, ⁵Department of Radiology, Moffitt Cancer Center and Research Center, Tampa,, FL, United States, ⁶Department of Integrated Mathematical Oncology, Moffitt Cancer Center and Research Institute, Tampa,, FL, United States, ⁷Department of Oncologic Sciences, University of South Florida, Tampa, FL, United States, ⁸Department of Radiation Oncology, Moffitt Cancer Center and Research Center, Tampa,, FL, United States, ⁹National Cancer Institute, National Institutes of Health, Bethesda, MD, United States, ¹⁰Department of Neuro-Oncology, Moffitt Cancer Center and Research Center, Tampa,, FL, United States

Synopsis

Keywords: Segmentation, Machine Learning/Artificial Intelligence, Glioblastoma, immunotherapy, radiotherapyConfounding appearance of radiographic changes in recurrent high grade glioma (HGG) patients treated with multimodality immunotherapy presents a challenge to the neuro-radiologist. A clinical need exists to improve upon conventional criteria for assessment of GBM on standard-of-care (SOC; T1w, T2w, FLAIR, and T1w-enhanced) MRI to help distinguish treatment-related effects from true disease progression. We have investigated the feasibility of intensity-based segmentation of tumor tissue types on multiparametric MRI (mpMRI) to inform response assessment in HGG patients treated with bevacizumab, hypofractionated stereotactic radiotherapy, and pembrolizumab.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.